This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.

• Drug: MORAb-003 (farletuzumab)
  MORAb-003 1.25 mg/kg infusions will take place weekly, i.e. on Day1 and week1 of each 21-day cycle.
• Drug: MORAb-003 (farletuzumab)
  MORAb-003 2.5mg/kg infusions will take place weekly, i.e. on Day1 and week1 of each 21-day cycle.
• Drug: 0.9% Saline
  0.9% infusions will take place weekly, i.e. on Day1 and week1 of each 21-day cycle

• 1: Active Comparator
  Carboplatin and taxane with MORAb-003 1.25 mg/kg
  Intervention: Drug: MORAb-003 (farletuzumab)
• 2: Active Comparator
  Carboplatin and taxane with MORAb-003 2.5 mg/kg
  Intervention: Drug: MORAb-003 (farletuzumab)
• 3: Placebo Comparator
  Carboplatin and taxane with Placebo
  Intervention: Drug: 0.9% Saline

Inclusion Criteria:

• A histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
• Must have measurable disease by CT or MRI scan
• Must have relapsed radiologically within ≥6 and < 24 months of completion of first-line platinum/taxane chemotherapy
• Must be a candidate for repeat carboplatin/taxane therapy
• Neurologic function: neuropathy (sensory and motor) ≤CTCAE Grade 1

Exclusion Criteria:

• Subjects who never responded to first-line platinum-based therapy or whose first relapse occurs <6 months or >24 months from the last platinum therapy
• Subjects who have received other therapy to treat their ovarian cancer since relapse
• Known central nervous system (CNS) tumor involvement
• Evidence of other active invasive malignancy requiring treatment in the past 5 years
• Known allergic reaction to a prior monoclonal antibody therapy or have any documented HAHA
• Previous treatment with MORAb-003 (farletuzumab)
• Clinical contraindications to use of a taxane